Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.

O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M; Respiratory Syncytial Virus (RSV) Prevention study group.

Lancet Infect Dis. 2015 Dec;15(12):1398-408. doi: 10.1016/S1473-3099(15)00247-9. Epub 2015 Nov 4.

PMID:
26511956
2.

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.

Robbie GJ, Makari D, Harris B, Losonsky GA, Jafri HS.

Infect Dis Ther. 2014 Dec;3(2):203-14. doi: 10.1007/s40121-014-0042-x. Epub 2014 Sep 30.

3.

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.

Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP; Motavizumab Study Group.

Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240.

PMID:
24356256
4.

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.

Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP.

Antimicrob Agents Chemother. 2013 Dec;57(12):6147-53. doi: 10.1128/AAC.01285-13. Epub 2013 Sep 30.

5.

Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection.

Anderson EJ, Simões EA, Buttery JP, Dennehy PH, Domachowske JB, Jensen K, Lieberman JM, Losonsky GA, Yogev R.

J Pediatric Infect Dis Soc. 2012 Sep;1(3):212-22. doi: 10.1093/jpids/pis069. Epub 2012 Jul 3.

PMID:
26619409
6.

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.

Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP; Motavizumab Cardiac Study Group.

Pediatr Res. 2011 Aug;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553.

PMID:
21522037
7.

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.

Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.

J Infect Dis. 2011 Mar 1;203(5):674-82. doi: 10.1093/infdis/jiq100. Epub 2011 Jan 5.

8.

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.

Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA; Motavizumab Study Group.

BMC Pediatr. 2010 Jun 3;10:38. doi: 10.1186/1471-2431-10-38.

9.

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group.

Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.

PMID:
20008423
10.

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.

Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.

Pediatr Infect Dis J. 2009 Sep;28(9):835-7. doi: 10.1097/INF.0b013e3181a165e4.

PMID:
19636278
11.

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.

Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, Losonsky GA; Motavizumab Study Group.

Pediatr Infect Dis J. 2009 Apr;28(4):267-72. doi: 10.1097/INF.0b013e31818ffd03.

PMID:
19258920
12.

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, Reisinger K, Chandler P, Hilty M, Walker RE, Gomez MM, Losonsky GA.

Vaccine. 2008 Nov 25;26(50):6373-82. doi: 10.1016/j.vaccine.2008.09.018. Epub 2008 Sep 24.

PMID:
18822334
13.

Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.

Wu H, Pfarr DS, Losonsky GA, Kiener PA.

Curr Top Microbiol Immunol. 2008;317:103-23. Review.

PMID:
17990791
14.

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK.

Clin Immunol. 2003 Sep;108(3):241-7.

PMID:
14499247
17.

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.

Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.

Infect Immun. 2002 Apr;70(4):2016-21.

18.

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.

Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI.

Infect Immun. 2001 Jun;69(6):3581-90.

19.

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr, Nichols R, Edelman R, Bridwell M, Monath TP.

Infect Immun. 2001 Feb;69(2):988-95.

20.

Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.

Rennels MB, Englund JA, Bernstein DI, Losonsky GA, Anderson EL, Pichichero ME, Munoz FM, Wolff MC.

Pediatr Infect Dis J. 2000 May;19(5):417-23.

PMID:
10819337
21.

Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM.

Infect Immun. 2000 Mar;68(3):1034-9.

22.

Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain.

Samandari T, Kotloff KL, Losonsky GA, Picking WD, Sansonetti PJ, Levine MM, Sztein MB.

J Immunol. 2000 Feb 15;164(4):2221-32.

23.

Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.

Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, Anderson EL, Steinhoff MC, Edwards KM.

Pediatrics. 2000 Jan;105(1):e12.

PMID:
10617749
24.

Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139.

Cohen MB, Giannella RA, Losonsky GA, Lang DR, Parker S, Hawkins JA, Gunther C, Schiff GA.

Infect Immun. 1999 Dec;67(12):6346-9.

25.

Validation of a gastrointestinal explant system for measurement of mucosal antibody production.

Losonsky GA, Fantry GT, Reymann M, Lim Y.

Clin Diagn Lab Immunol. 1999 Nov;6(6):803-7.

26.

Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.

Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, Losonsky GA, Alegria S, Levine MM.

J Infect Dis. 1999 Nov;180(5):1709-12.

PMID:
10515838
27.

Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.

Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C, Levine MM.

Pediatr Infect Dis J. 1999 Jul;18(7):624-30.

PMID:
10440439
28.

Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Losonsky GA, Wasserman SS, Levine MM, Cryz SJ.

Infect Immun. 1999 Apr;67(4):2030-4.

29.

Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization.

Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, Dulkerian S, West DJ, Gewolb IH.

Pediatrics. 1999 Feb;103(2):E14.

PMID:
9925860
30.

A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Perry RT, Plowe CV, Koumaré B, Bougoudogo F, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM.

Bull World Health Organ. 1998;76(1):63-71.

31.

Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.

Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM.

Lancet. 1998 May 16;351(9114):1472-6.

PMID:
9605803
32.

Validation of a volunteer model of cholera with frozen bacteria as the challenge.

Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky GA, Shimko J, Nataro JP, Edelman R, Levine MM, Giannella RA, Schiff G, Lang D.

Infect Immun. 1998 May;66(5):1968-72.

33.

Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.

Losonsky GA, Lim Y, Motamedi P, Comstock LE, Johnson JA, Morris JG Jr, Tacket CO, Kaper JB, Levine MM.

Clin Diagn Lab Immunol. 1997 May;4(3):264-9.

34.

A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens.

Galen JE, Gomez-Duarte OG, Losonsky GA, Halpern JL, Lauderbaugh CS, Kaintuck S, Reymann MK, Levine MM.

Vaccine. 1997 Apr-May;15(6-7):700-8.

PMID:
9178472
35.

Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Pickard D, Dougan G, Chatfield SN, Levine MM.

Infect Immun. 1997 Feb;65(2):452-6.

36.

Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans.

Morris JG Jr, Sztein MB, Rice EW, Nataro JP, Losonsky GA, Panigrahi P, Tacket CO, Johnson JA.

J Infect Dis. 1996 Dec;174(6):1364-8.

PMID:
8940236
37.

No adverse impact on protection against pertussis from combined administration of Haemophilus influenza type b conjugate and diphtheria-tetanus toxoid-pertussis vaccines in the same syringe.

Levine OS, Lagos R, Losonsky GA, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine MM.

J Infect Dis. 1996 Dec;174(6):1341-4.

PMID:
8940230
38.

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM.

Infect Immun. 1996 Nov;64(11):4542-8.

39.

Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.

Losonsky GA, Yunyongying J, Lim V, Reymann M, Lim YL, Wasserman SS, Levine MM.

Infect Immun. 1996 Jan;64(1):10-5.

40.

A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.

Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM.

Vaccine. 1995 Nov;13(16):1488-94.

PMID:
8578831
41.

Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.

Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM.

Vaccine. 1995 Apr;13(5):495-502.

PMID:
7639017
42.

Kinetics of the vibriocidal antibody response to live oral cholera vaccines.

Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castañeda E, Levine MM.

Vaccine. 1994 Aug;12(11):1000-3.

PMID:
7975839
43.
44.

Serum antibody responses of divers to waterborne pathogens.

Losonsky GA, Hasan JA, Huq A, Kaintuck S, Colwell RR.

Clin Diagn Lab Immunol. 1994 Mar;1(2):182-5.

45.

Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect.

Wasserman SS, Kotloff KL, Losonsky GA, Levine MM.

Am J Epidemiol. 1993 Dec 1;138(11):988-93.

PMID:
8256784
47.

A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants.

Pichichero ME, Marsocci SM, Francis AB, Green JL, Disney FA, Rennels MB, Lewis ED, Sugarman L, Losonsky GA, Zito E, et al.

Vaccine. 1993;11(7):747-53.

PMID:
8393606
48.
49.
50.

Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus.

Padilla-Noriega L, Fiore L, Rennels MB, Losonsky GA, Mackow ER, Greenberg HB.

J Clin Microbiol. 1992 Jun;30(6):1392-7.

Supplemental Content

Loading ...
Support Center